NYSEARCA:THNR Amplify Weight Loss Drug & Treatment ETF (THNR) Price, Holdings, & News $25.40 -0.46 (-1.78%) As of 07/31/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsBuy This Stock About Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get THNR alerts:Sign Up Key Stats Today's Range$25.30▼$25.4050-Day Range$23.79▼$26.7552-Week Range$21.70▼$27.28Volume1,659 shsAverage Volume2,058 shsMarket Capitalization$5.08 millionAssets Under Management$5.15 millionDividend YieldN/ANet Expense Ratio0.59%Aggregate RatingModerate Buy ETF Overview The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments. Read More Amplify Weight Loss Drug & Treatment ETF ExpensesTypeTHNRTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.59%0.57%0.57%0.51%0.53%Other Expenses0.00%0.58%0.55%0.58%0.55%Total Expense0.59%0.73%0.76%0.74%0.73%Fee Waiver0.00%-0.75%-0.64%-0.70%-0.62%Net Expense0.59%0.60%0.63%0.58%0.60% Receive THNR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Weight Loss Drug & Treatment ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. THNR ETF News HeadlinesAmplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Shares Up 0.3% - Still a Buy?July 21, 2026 | americanbankingnews.comETFs tied to HIMS gain attention as the telehealth stock spikesMarch 9, 2026 | msn.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 1 at 1:00 AM | Porter & Company (Ad)Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFsSeptember 18, 2025 | benzinga.comWhy Investors Haven't Feasted on Two New Weight-Loss ETFsJune 24, 2024 | investopedia.comSee More Headlines THNR ETF - Frequently Asked Questions How have THNR shares performed this year? Amplify Weight Loss Drug & Treatment ETF's stock was trading at $25.22 at the start of the year. Since then, THNR shares have increased by 0.7% and is now trading at $25.40. How do I buy shares of Amplify Weight Loss Drug & Treatment ETF? Shares of THNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amplify Weight Loss Drug & Treatment ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Weight Loss Drug & Treatment ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), NiCE (NICE) and Intellia Therapeutics (NTLA). Fund Details IssuerAmplify Fund NameAmplify Weight Loss Drug & Treatment ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:THNR Inception Date5/21/2024 Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings22 Fund Statistics Assets Under Management$5.15 million Average Daily Volume$0.00 Discount/Premium0.13% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments, LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerGTS Miscellaneous Outstanding Shares200,000Beta0.37 Creation Unit10,000 Creation Fee$300.00 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report Top 10 THNR HoldingsNovo Nordisk A/S (NYSE:NVO)Holding Weight: 9.78%Eli Lilly and Company (NYSE:LLY)Holding Weight: 9.08%Innovent Biologics, Inc.Holding Weight: 5.53%Arrowhead Pharmaceuticals (NASDAQ:ARWR)Holding Weight: 5.40%CSPC Pharmaceutical Group LimitedHolding Weight: 5.31%AbbVie (NYSE:ABBV)Holding Weight: 5.29%Hims & Hers Health (NYSE:HIMS)Holding Weight: 5.25%Scholar Rock (NASDAQ:SRRK)Holding Weight: 5.12%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.08%Roche Holding AGHolding Weight: 5.02%Full Holdings DetailsTHNR Sector ExposureTHNR Industry Exposure This page (NYSEARCA:THNR) was last updated on 8/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Weight Loss Drug & Treatment ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Weight Loss Drug & Treatment ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
